2024
Recovery From Severe Heart Failure in a Patient With Primary Hyperoxaluria Type 1 After Treatment With Lumasiran, Pyridoxine, and Kidney Transplant
Choi M, Kahl A, Hawkins-van der Cingel G, Noriega M, Klingel K, Doeblin P, Schoenrath F, Eckardt K, Öllinger R, Knauf F, Halleck F. Recovery From Severe Heart Failure in a Patient With Primary Hyperoxaluria Type 1 After Treatment With Lumasiran, Pyridoxine, and Kidney Transplant. Annals Of Internal Medicine Clinical Cases 2024, 3 DOI: 10.7326/aimcc.2023.1428.Peer-Reviewed Original Research
2023
Heart Failure Recovery After Lumasiran and Isolated Kidney Transplantation in Primary Hyperoxaluria Type 1
der Cingel G, Choi M, Kahl A, Schoenrath F, Rehse G, Eckardt K, Knauf F, Halleck F. Heart Failure Recovery After Lumasiran and Isolated Kidney Transplantation in Primary Hyperoxaluria Type 1. Journal Of The American Society Of Nephrology 2023, 34: 565-565. DOI: 10.1681/asn.20233411s1565d.Peer-Reviewed Original Research
2020
Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient
Kempf C, Pfau A, Holle J, Müller-Schlüter K, Bufler P, Knauf F, Müller D. Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient. Pediatric Nephrology 2020, 35: 1787-1789. PMID: 32418144, PMCID: PMC7385015, DOI: 10.1007/s00467-020-04585-5.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseLactate dehydrogenase 5Urinary oxalateAdvanced chronic kidney diseaseAnti-convulsive drugsMultisystemic metabolic disorderLiver-kidney transplantationMajority of patientsCurrent standard treatmentTreatment of childrenHyperoxaluria type 1Anuric infantsPH patientsUox excretionRenal diseaseDravet syndromeKidney diseasePrimary hyperoxaluriaCompassionate useStandard treatmentPlasma concentrationsMetabolic disordersPromising drugEarly infancy